Confronto
Maridebart Cafraglutide vs. Survodutide
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Metabolico
Metabolico
N. CAS
nessun dato
2179963-22-7
Peso molecolare
nessun dato
4727 g/mol
Emivita
nessun dato
168 h
Sequenza
nessun dato
modifiziertes 29-Aminosäuren-Peptid mit FettsäureseitenketteMeccanismo d'azione
Maridebart Cafraglutide
MariTide combines GLP-1 receptor agonism with GIP receptor antagonism in an antibody-peptide conjugate. Its long duration of action allows infrequent (monthly) dosing.
Survodutide
Survodutide is a dual agonist at the GLP-1 and glucagon receptors. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at high blood glucose and modulation of satiety. The glucagon component raises basal energy expenditure via hepatic and brown adipocyte effects. A fatty-acid side chain enables albumin binding and weekly dosing.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
1
4
di cui sull'uomo
1
4
Effetti registrati
2
3
Contraddizioni aperte
0
1
Eventi avversi documentati
1
2
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Maridebart Cafraglutide and Survodutide?
- Maridebart Cafraglutide is classified as "Metabolico", while Survodutide is classified as "Metabolico". Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. Survodutide: Synthetic peptide that simultaneously activates the GLP-1 and glucagon receptors. Developed by Boehringer Ingelheim and Zealand Pharma; in phase-3 trials for obesity (SYNCHRONIZE) and MASH. No marketing approval yet. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Maridebart Cafraglutide or Survodutide?
- The highest available evidence level is "RCT sull'uomo" for Maridebart Cafraglutide and "RCT sull'uomo" for Survodutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Maridebart Cafraglutide and Survodutide in Germany and the United States?
- Germania: Maridebart Cafraglutide — Non approvato, Survodutide — Non approvato. Stati Uniti: Maridebart Cafraglutide — Non approvato, Survodutide — Non approvato. These are factual summaries with source and review date on the individual pages.